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ABSTRACT
Introduction: The high prevalence of insulin
resistance in women with polycystic ovary syndrome
(PCOS) is considered to be one of the major
pathophysiological changes in PCOS that leads to
anovulatory infertility. We hypothesise that
electroacupuncture pretreatment improves insulin
sensitivity and leads to a higher ovulation rate and
greater chances of live birth after the induction of
ovulation. The effect of electroacupuncture
pretreatment followed by ovulation induction in women
with anovulatory PCOS has not been investigated
before, and we present here a randomised controlled
trial to test this hypothesis by comparing
electroacupuncture pretreatment followed by letrozole
versus letrozole alone in anovulatory women
with PCOS.
Methods/analysis: This is a multicentre, randomised,
and controlled trial. A total of 384 patients will be
enrolled in this study and will be randomly allocated
by a central randomisation system to the treatment
group or the control group in a 1:1 ratio. The treatment
group will undergo 16 weeks of electroacupuncture
pretreatment followed by 4 cycles of letrozole, and the
control group will only undergo 4 cycles of letrozole.
The primary outcome will be the live birth rate. All
statistical analyses will be performed using the SPSS
program V.21.0 (SPSS, Chicago, Illinois, USA), and
a p value <0.05 will be considered statistically
significant.
Ethics/dissemination: This study has been approved
by the ethics committees of each participating centre.
Written consent will be obtained from each patient and
her husband before any study procedure is performed.
Adverse events will be categorised, and the percentage
of patients experiencing adverse events or serious
adverse events during the treatment period will be
documented. The results of this trial will be
disseminated in peer-reviewed journals and presented
at international meetings.
Trial registration number: NCT02491333.
BACKGROUND
Polycystic ovary syndrome (PCOS) is a
common endocrine and metabolic disorder
affecting 6–10% of women of reproductive
age,1 and it accounts for 70–80% of anovula-
tory infertility.2 PCOS is characterised by
amenorrhoea, hirsutism, acne, obesity, poly-
cystic ovaries and infertility, and it can have
serious effects on the general health and
quality of life. Insulin resistance (IR),
Strengths and limitations of this study
▪ This is the first randomised controlled trial com-
paring electroacupuncture pretreatment followed
by letrozole versus letrozole alone on live birth in
anovulatory infertile women with polycystic ovary
syndrome (PCOS).
▪ This is the first trial that seeks to improve insulin
sensitivity in women with PCOS by using elec-
troacupuncture as the pretreatment.
▪ Complications during pregnancy will also be
recorded to verify the prospective effects of acu-
puncture on women with PCOS in this study.
▪ Placebo or sham acupuncture will not be offered
in the control group because it might not be
truly inert and might still have some physio-
logical effects.
▪ The researchers, acupuncturists and the partici-
pants cannot be blinded to treatment allocation.
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hyperinsulinaemia and dyslipidaemia worsen with
ageing, and the risk of miscarriage is three times greater
in women with PCOS compared with healthy women.3
Women with PCOS are also at an increased risk of preg-
nancy complications such as impaired glucose tolerance,
gestational diabetes mellitus, pregnancy-induced hyper-
tension and pre-eclampsia, and small for gestational age
(SGA) children.3 Thus, the metabolic abnormalities of
PCOS can affect the woman’s health as well as that of
her children.3
Ovulation induction in women with PCOS suffering
from anovulatory infertility includes the use of antioes-
trogen, insulin sensitisers, aromatase inhibitors, gonado-
tropin and surgical treatment.4 Clomiphene citrate has
been the ﬁrst-line medication, but a recent large multi-
centre randomised study5 demonstrated that letrozole,
an aromatase inhibitor, results in a higher ovulation rate
and a higher live birth rate than clomiphene citrate.
Despite the fact that pharmacological methods of ovu-
lation induction are often effective, a large number of
patients still have difﬁculty conceiving and they have a
high risk of miscarriage that might be related to reduced
endometrial receptivity.6 The high prevalence of IR (up
to 60%) in women with PCOS is considered to be one of
the major pathophysiological changes in PCOS7 8 and
studies indicate that IR and hyperinsulinaemia affect
endometrial receptivity in many ways, leading to difﬁculty
in conceiving and an increase in miscarriage.6
Acupuncture is becoming popular in research and
clinical practice, and recent studies indicate that acu-
puncture can increase the ovulation rate,9–11 improve
endocrine proﬁle by decreasing circulating sex steroids,
increase menstrual frequency12 13 and decrease
weight.14 15 It has been shown that acupuncture can regu-
late endogenous systems, including the sympathetic
nervous system, the endocrine system and the neuroendo-
crine system.16 17 Acupuncture appears to improve endo-
metrial receptivity in rats18 19 by decreasing the
impedance of the uterine artery blood ﬂow and improv-
ing the blood ﬂow to the uterus,20 which might enhance
implantation and increase the chances of successful
pregnancy and live birth.
Furthermore, electroacupuncture has been shown
to improve insulin sensitivity in experimental trials.
Electroacupuncture can signiﬁcantly enhance the decrease
in blood glucose levels after insulin injection, suggesting
an improvement in insulin sensitivity.21 The result indi-
cates that electroacupuncture improves glucose tolerance
both in wild-type and transgenic mice fed a high-fat diet,
and that the effect is related to the stimulation parameters
used and is probably due to the reduction of free fatty
acid.21 In rat PCOS models, repeated acupuncture has
also been demonstrated to normalise insulin sensitivity.22 23
Another study showed that electroacupuncture can nor-
malise insulin sensitivity, and ameliorate IR and hyperinsu-
linemia in rats with PCOS, probably by regulating the
function of pancreatic islets β-cells and by reducing oxida-
tive stress and free androgen.24 During stimulation,
electroacupuncture improves insulin sensitivity in a
dihydrotestosterone-induced rat PCOS model more than
does acupuncture with manual stimulation. However, post-
stimulation, both electrical stimulation and manual stimu-
lation show equal effects, and this might be due to the
activation of sensory afferents by both methods.25
Until now, there are still no studies investigating
whether low-frequency electroacupuncture pretreatment
followed by ovulation induction will increase the live
birth rate. On the basis of previous studies, we hypothe-
sise that acupuncture pretreatment improves insulin sen-
sitivity and leads to a higher ovulation rate and higher
live birth rate. This study is intended to test this
hypothesis.
OBJECTIVE
The objective of this multicentre randomised controlled
trial (RCT) is to evaluate whether 16 weeks of acupunc-
ture pretreatment followed by letrozole compared with
letrozole alone leads to a higher live birth rate in
Chinese women with PCOS and anovulatory infertility.
METHODS/DESIGN
Study design
This is a multicentre, randomised, and controlled trial
comparing the live birth rate after acupuncture pretreat-
ment followed by letrozole versus letrozole alone for
ovulation induction in Chinese women with PCOS and
anovulatory infertility. Reporting of the study results will
follow the STRICTA26 and CONSORT guidelines.27
This study is referred to as the Clinical Trial of
Acupuncture Pre-treatment on PCOS (PCOSAPct). It
has been registered at clinicaltrial.gov (NCT02491320)
and with the Chinese Clinical Trials Registry
(ChiCTR-ICR-15006640).
Participants
A total of 384 women with PCOS and anovulatory infer-
tility will be recruited from three hospitals in mainland
China: the Department of Traditional Chinese Medicine
in the First Afﬁliated Hospital of Guangzhou Medical
University, the Department of Gynecology in Xuzhou
Maternity and Child Health Hospital, and the Department
of Traditional Chinese Medicine in Hexian Memorial
Afﬁliated Hospital of Southern Medical University. Each
centre will screen participants until the target population
of 128 participants/site is achieved. After detailed explan-
ation, counselling and signing the informed consent form,
the eligible participants will be randomly allocated to
either the electroacupuncture pretreatment with letrozole
group or the letrozole-only group.
Inclusion criteria
1. Women aged between 20 and 40 years.
2. Conﬁrmed diagnosis of PCOS according to the
Rotterdam criteria: oligomenorrhoea (an intermenstrual
interval>35 days or <8 cycles in the past year) or
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amenorrhoea (an intermenstrual interval>90 days)
together with polycystic ovarian morphology, that is,
the presence of ≥12 antral follicles (≤9 mm) and/or
ovarian volume >10 mL on transvaginal scanning,
and/or clinical or biochemical hyperandrogenism.
Clinical hyperandrogenism in China is deﬁned as a
Ferriman-Gallwey (FG) score ≥5,28 and biochemical
hyperandrogenism is deﬁned as total testosterone (T)
>2.6 nmol/L and free testosterone ≥6.0 pg/mL.29
3. A husband whose sperm concentration meets the
WHO standards (2010) of ≥15×106/mL and a total
motility of ≥40% or a total motile sperm count of ≥9
million.
4. At least one patent tube shown by hysterosalpingo-
gram or diagnostic laparoscopy within 3 years if the
patient does not have a history of abortion or pelvic
operation. If the patient has a history of pregnancy
and no history of pelvic operation within the past
5 years, she is not required to undergo a tubal
patency test.
Exclusion criteria
1. Exclusion of other endocrine disorders:
▸ Patients with hyperprolactinaemia (deﬁned as 2
prolactin (PRL) levels of ≥25 ng/mL at least
1 week apart or as determined by local normative
values). The goal of eliminating patients with
documented hyperprolactinaemia is to decrease
the heterogeneity of the PCOS population.
These patients might be candidates for ovulation
induction with alternate regimens (dopamine
agonists). A normal level within the past year or
being on treatment is adequate for entry.
▸ Patients with follicle-stimulating hormone (FSH)
levels >15 mIU/mL. A normal level within the
past year is adequate for entry.
▸ –Patients with uncorrected thyroid disease
(deﬁned as thyroid-stimulating hormone (TSH)
<0.2 or >5.5 mIU/mL). A normal level within the
past year is adequate for entry.
▸ Patients diagnosed with type I or type II diabetes
who are poorly controlled (deﬁned as a glycated
haemoglobin (HbA1c) level >7.0%) or patients
receiving antidiabetic medications such as
insulin, thiazolidinediones, acarbose or sulfony-
lureas that are likely to confound the effects of
electroacupuncture. Patients currently receiving
metformin XR (extended release) for a diagnosis
of type I or type II diabetes or for PCOS are also
speciﬁcally excluded.
▸ Patients with suspected Cushing’s syndrome.
2. Use of hormonal or other medication, including
Chinese herbal prescriptions, in the past 2 months
that might affect the outcome of the study treatment.
3. Acupuncture in the past 2 months.
4. Pregnancy within the past 6 weeks.
5. Abortion or having given birth in the past 6 weeks.
6. Breast feeding within the past 6 months.
7. Not willing to give written consent to the study.
8. Patients enrolled simultaneously in other investiga-
tive studies that require medications, prohibit the
use of the study medications, limit intercourse or
otherwise prevent compliance with the study
protocol.
9. Patients who anticipate taking longer than a
1 month break from treatments during the study
protocol.
10. Additional exclusion criteria:
A. Patients with a suspected adrenal or ovarian
tumour that is secreting androgens.
B. Couples with previous sterilisation procedures
(vasectomy, tubal ligation) that have been
reversed. The prior procedure might affect the
study outcomes, and patients with both a
reversed sterilisation procedure and PCOS are
rare enough that exclusion should not adversely
affect recruitment.
C. Participants who have undergone a bariatric
surgery procedure in the recent past
(<12 months) and are in a period of acute weight
loss or who have been advised against pregnancy
by their bariatric surgeon.
D. Patients with untreated or poorly controlled
hypertension deﬁned as a systolic blood pressure
of 160 mm Hg or a diastolic blood pressure of
100 mm Hg obtained on two occasions at least
60 min apart.
E. Patients with known congenital adrenal
hyperplasia.
F. Patients on oral contraceptives, depot progestins
or hormonal implants (including Implanon). A
2-month washout period will be required prior
to screening for patients on these agents.
Longer washouts might be necessary for certain
depot contraceptive forms or implants, especially
when the implants are still in place. A 2-month
washout will be required for patients on oral
cyclic progestins.
G. Patients with liver (LR) disease deﬁned as aspar-
tate aminotransferase (AST) or alanine amino-
transferase (ALT) >2 times normal or total
bilirubin >2.5 mg/dL or patients with renal
disease deﬁned as blood urea nitrogen (BUN)
>30 mg/dL or serum creatinine >1.4 mg/dL.
H. Patients with signiﬁcant anaemia (haemoglobin
<10 g/dL).
I. Patients with a history of deep venous throm-
bosis, pulmonary embolus or cerebrovascular
accident.
J. Patients with known heart disease that is likely to
be exacerbated by pregnancy.
K. Patients with a history of, or suspected, cervical
carcinoma, endometrial carcinoma or breast car-
cinoma. A normal Pap smear or thinprep cytolo-
gic test (TCT) result will be required for women
21 years and older.
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L. Patients with a current history of alcohol abuse.
Alcohol abuse is deﬁned as >14 drinks/week or
binge drinking.
M. Patients taking other medications known to
affect reproductive function or metabolism.
These medications include oral contraceptives,
gonadotropin-releasing hormone (GnRH) ago-
nists and antagonists, antiandrogens, gonadotro-
pins, antiobesity drugs, Chinese herbal formulas,
antidiabetic drugs such as metformin and thiazo-
lidinediones, somatostatin, diazoxide, ACE inhi-
bitors and calcium channel blockers. The
washout period for all of these medications will
be 2 months.
Randomisation and allocation concealment
A central randomisation system will be used to allocate
patients. The random number sequence will be gener-
ated by computer software and the allocation sequence
will be made by Chinese Clinical Trial Registry with the
web-based Research Management (ResMan) database.
When a new participant is enrolled, the allocation infor-
mation will be recorded with a special code in ResMan.
There is no way to speculate on the allocation status of
the participant before getting this information.
The patients in the treatment group will receive acu-
puncture treatment before ovulation induction, but the
control group will not receive acupuncture treatment.
Since the intervention in this study consists of the distri-
bution of acupuncture, the researchers, acupuncturists
and participants cannot be blinded to treatment alloca-
tion. To prevent contamination, participants in the treat-
ment group will not be allowed to contact the control
participants.
Interventions
Eligible patients will be randomised into one of the two
arms.
Treatment group—a 16-week acupuncture pretreat-
ment followed by letrozole. Electroacupuncture treat-
ment will start on days 3–5 after a spontaneous period
or after a withdrawal bleeding following progestin
(100 mg twice a day for 5 days, Zhejiang Xianju
Pharmaceutical Co, Taizhou). All participants will be
requested to use contraception during the 16-week pre-
treatment with electroacupuncture according to a ﬁxed
protocol (see below). They will receive electroacupunc-
ture treatment three times a week. Each treatment
session will last for 30 min, with a maximum of 48 treat-
ment sessions over 16 weeks. After 16 weeks of acupunc-
ture treatment, letrozole will start on days 2–3 after a
spontaneous period or after a withdrawal bleeding after
progestin administration. The participants will be
treated for up to four cycles, and they will be instructed
to have intercourse on a regular basis during the cycles.
Control group—letrozole only. Letrozole will be
started on days 3–5 after a spontaneous period or a with-
drawal bleeding following progestin. Participants will be
treated for up to four cycles, and they will be instructed
to have intercourse on a regular basis during the cycles.
Acupuncture protocol
The rationale for the acupuncture protocol is based on
traditional Chinese and Western medical theories,
and the study protocol follows the CONSORT27 and
STRICTA26 recommendations with detailed descriptions
of the treatment, including the number of needles used,
how the needles will be stimulated (manual, electrical),
the frequency of the sessions and the length of treat-
ment period. We will use a ﬁxed acupuncture protocol.
Acupuncture treatment will start on days 3–5 after a
spontaneous period or after a withdrawal bleeding fol-
lowing progestin. All participants will receive acupunc-
ture treatment for three sessions a week. Each treatment
session will last for 30 min, and there will be a maximum
of 48 treatment sessions over the 16 weeks. The acu-
puncture protocol of this RCT follows the protocol
inClinicalTrial.gov NCT01457209 and NCT02026323.
Acupuncture treatment will be given by a Traditional
Chinese Medicine doctor with a master’s degree and at
least 1 year of clinical experience in acupuncture.
Before the start of the study, we will conduct a one-day
study-speciﬁc education, including theoretical sessions
with a traditional Chinese and Western medical
approach to acupuncture physiology, practical sessions
with demonstrations of acupuncture treatment and
lectures on research methodology with a focus on RCTs.
Disposable, single-use, sterilised needles made of stain-
less steel, 0.25 mm×30 mm and 0.30 mm×40/50 mm
(Huanqiu, Suzhou Acupuncture Goods Co, Suzhou,
China), will be inserted to a depth of 15–35 mm in
segmental acupuncture points. Two sets of acupuncture
points will be alternated every other treatment
(table 1).30 The ﬁrst set will consist of conception vessel
(CV) 3, CV12 and stomach (ST) 29 bilaterally and in the
muscles above the knee, ST34 and ST33 bilaterally and
below the knee, and spleen (SP) 6 and ST36. Needles
will also be placed bilaterally in the extrasegmental large
intestine (LI) 4 acupuncture point that does not innerv-
ate the ovaries. In total, 14 needles will be placed, and
all will be stimulated manually by rotating the needle to
evoke needle sensation (DeQi) once inserted. The
following points will be connected to an electrical
stimulator (Export Abteilung, Schwa-Medico GmbH,
Wetzlarer Str. 41-43; 35630 Ehringshausen): CV3 to
CV12, ST29 bilateral, and ST34 to ST33 bilateral.
Electroacupuncture stimulation will be given at a fre-
quency of 2 Hz with a 0.3 ms pulse length and intensity
adjusted to produce local muscle contractions without
pain or discomfort. Needles not connected to the elec-
trical stimulator will be manually stimulated to evoke
needle sensation every 10 min for a total of four stimula-
tions. The second set consists of 14 needles placed in
segmental abdominal points ST27 bilaterally and CV6
connected to CV10 (electrical stimulation), leg points
SP10 connected to a non-acupuncture point located
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Table 1 Acupuncture protocol30
Point Stimulation Location Muscle
Muscle
innervation
Set 1
Zhongji (CV3) EA 4 cun caudal to the umbilicus Fibrous tissue, linea alba L1
Zhongwan (CV12) EA On the midline, 4 cun superior to the umbilicus Fibrous tissue, linea alba Th7–8
Guilai (bilateral) (ST29) EA 1 cun cranial to the pubic bone and 2 cun lateral to the midline M. rectus abdominis Th6–12
Liangqiu (bilateral) (ST34) EA 2 cun above the superior lateral border of the patella on the line
connecting the anterior superior iliac spine found with the knee flexed
M. quadriceps femoris Femoral nerve
Yinshi (bilateral) (ST33) EA 3 cun above the superior lateral border of the patella on the line
connecting the anterior superior iliac spine found with the knee flexed
M. quadriceps femoris Femoral nerve
Sanyinjiao (bilateral) (SP6) DeQi 4
times
3 cun proximal to the medial malleolus Mm. flexor digitorum longus,
tibialis posterior
L4–5, S1–2
Zusanli (bilateral) (ST36) DeQi 4
times
On the anterior lateral side of the leg, 3 cun below Dubi (ST35), one
finger width (middle finger) from the anterior crest of the tibia
M. tibialis anterior L4–5, S1
Hegu (bilateral) (LI4) DeQi 4
times
On the highest point at the musculi interosseus dorsalis Mm. interosseus dorsalis I,
lumbricalis II, adductor
pollicis
C8, Th1
Set 2
Daju (bilateral) (ST27) EA 3 cun cranial to the pubic bone and 2 cun lateral to the midline M. rectus abdominis Th6–12
Qihai (CV6) EA 1.5 cun caudal to the umbilicus Fibrous tissue, linea alba Th11
Xiawan (CV10) EA 2 cun cranial to the umbilicus Fibrous tissue, linea alba Th8
Extrameridian point (bilateral) EA 6 cun above the patella in line with SP10 M. quadriceps femoris L2–4
Xuehai (bilateral) (SP10) EA With the knee flexed, on the medial side of the thigh 2 cun above the
superior medial corner of the patella on the prominence of the medial
head of the quadriceps muscle of the thigh
M. quadriceps femoris L2–4
Sanyinjiao (bilateral) (SP6) DeQi 4
times
3 cun proximal to the medial malleolus Mm. flexor digitorum longus,
tibialis posterior
L4–5, S1–2
Taichong (bilateral) (LR3) DeQi 4
times
Between metatarsal I and II, just distal to the caput M. interosseus dorsalis I S2–3
Neiguan (bilateral) (PC6) DeQi 4
times
2 cun proximal to the processus styloideus radii, between the tendons
of the palmaris longus and the flexor carpi radialis
M. flexor digitorum
superficialis
C8, Th1
The two sets will be alternated for every other treatment.
C, cervical vertebra; CV, conception vessel; EA, electroacupuncture; L, lumbar vertebra; LI, large intestine; LR, liver; M., musculi; Mm., musculus; PC, pericardium; S, sacral vertebra; SP,
spleen; ST, stomach; Th, thoracic vertebra.
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6 cun proximal to the patella’s medial border (electrical
stimulation) and SP6, and LR3 bilaterally (manual stimu-
lation). Extrasegmental points are pericardium (PC) 6
bilaterally (manual stimulation).
Needle insertion technique
Needle insertion should be gentle. The depth of the
needle insertion will vary from patient to patient
depending on their body mass index (BMI), but they
should be placed deep enough to reach muscle/ﬁbrous
tissue. When the needles are inserted, they will be gently
rotated until DeQi (needle sensation reﬂecting activa-
tion of sensory afferents) is obtained. The needles con-
nected to the electric stimulator will be stimulated at
2 Hz and 300 revolutions per minute.
Letrozole
Patients in the treatment group following 16 weeks of
acupuncture pretreatment and those in the control
group will receive letrozole (Femara, Novartis
Pharmaceuticals, Basel, Switzerland) starting from
2.5 mg (1 pill) daily from days 3–5 after a spontaneous
period or after a withdrawal bleeding following progestin
and will continue for 5 days. If there is an adequate
response with ovulation (ie, the serum progesterone
level on the 3rd week of the cycle is higher than
3 ng/mL) or if the increase in progesterone is delayed
by 1 week, this dose will be maintained. In patients with
no response, the letrozole dose will be increased to 5 mg
(2 pills) a day for 5 days. If there is still no response, the
dose will be increased to 7.5 mg per day for 5 days in
the next cycle. The maximum daily dose of letrozole will
be 7.5 mg (3 pills) daily. Participants will be treated for
up to four cycles. If the patient becomes pregnant, the
treatment will be stopped.
Study-specific visits and procedures
The trial phase will involve treatment with electroacu-
puncture pretreatment for 16 weeks followed by four
cycles of letrozole or four cycles of letrozole alone
(ﬁgure 1). Patients will attend up to seven visits, includ-
ing the screening visit, baseline visit, treatment visit, end
of pretreatment visit, pregnancy visit, end of treatment
visit and follow-up visit. Adverse events and concomitant
Figure 1 The study flow chart Main Document. HOMA-IR, homeostatic model assessment of insulin resistance; PCOS,
polycystic ovary syndrome.
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medications will be recorded during every visit.
Face-to-face adherence reminder sessions will take place
at the initial product dispensing and at each study visit
thereafter. The overview of the study visits is shown in
table 2.
Screening visit
Participants who are interested in participating will ﬁrst
be screened by one of the principal investigators (PIs) to
verify that they meet the basic inclusion criteria (ie, age,
oligomenorrhoea, partner availability, etc). Those who
qualify will be scheduled for a screening visit.
Obtain signed informed consent
Every participant who agrees to participate in this study
must sign the informed consent form (see online
supplementary appendix 1). Participants will be mailed a
study packet with a copy of the informed consent
document and other relevant study materials for them to
review prior to the visit. The study will be explained in
detail, and all questions will be answered prior to signing
the written informed consent to participate in the study.
The husband will also be required to sign a consent form
at the time of the screening visit. It is important to obtain
his consent for participation in the study due to the
requirements of intercourse and semen analysis in
the inclusion criteria and the information collected on
the quality-of-life surveys. Additional blood and faeces
samples will be obtained from the patients to be stored
for DNA analysis and microbiological detection.
Complete physical examination
A complete physical examination, including height,
weight, hip and waist measurements, will be performed.
Height and weight will be recorded to the nearest
0.1 cm and 0.1 kg, respectively. Waist and hip
Table 2 Overview of study visits
Screening
visit
Baseline
visit
Treatment
visit
End of
pretreatment
visit
Pregnancy
visit
End of
treatment
visit
Follow-up
visit
Physical examination √ √
Menstrual cycle/
intercourse diary
√ √ √ √ √
Fasting blood samples
for metabolic and safety
profile
√ √
Fasting blood samples
for sex hormone
steroids
√ √
Preconception
counselling
√
Transvaginal ultrasound √ √ √ √
Questionnaire √ √
OGTT and insulin
release test
√ √ √
Pregnancy test √ √ √ √
Hysterosalpingogram √
Semen analysis √
TCT √
Serum progesterone √
Pregnancy and
neonatal records
√ √
Fasting phlebotomy and
faeces
√ √
Query for adverse event
and concomitant
medications
√ √ √ √ √ √ √
Physical examination: weight, height, waist circumference, hip circumference, FG/acne.
Fasting blood samples for metabolic and safety profile: FGLU, FINS, C peptide, HbA1c, TC, TG, HDL-C, LDL-C, CBC, renal and liver profile.
Fasting blood samples for sex hormone steroids: FSH, LH, SHBG, T, free testosterone, E2, TSH and PRL.
Transvaginal ultrasound: endometrial thickness, ovarian volume, antral follicle count, and size of ovarian cysts or developing follicles.
Preconception counselling: TORCH and HIV screening.
Fasting phlebotomy and faeces: serum for the central core laboratory and faeces for microbiological detection.
CBC, complete blood count; E2, estradiol; FG, Ferriman-Gallwey; FGLU, fasting blood glucose; FINS, fasting insulin; FSH, follicle-stimulating
hormone; HbA1c, glycated haemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LH,
luteinising hormone; OGTT, oral glucose tolerance test; PRL, prolactin; SHBG, sex hormone-binding globulin, T, total testosterone; TC, total
cholesterol; TCT, thinprep cytologic test; TG, triglycerides; TORCH, Toxoplasmosis, Rubella, Cytomegalovirus, and Herpes virus; TSH,
thyroid-stimulating hormone.
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circumference will be recorded to the nearest 1 cm.
Hirsutism will be assessed by FG and acne by standard
acne lesion counts; also, a pelvic examination with Pap
smear or TCT will be performed.
Transvaginal ultrasound of the uterus and ovaries
A. Uterine dimensions, endometrial thickness and echo
type, other uterine abnormalities, and the presence
and size of leiomyoma will be obtained through
transvaginal ultrasound.
B. Ovarian size in three dimensions, the size of the
largest ovarian follicle/cyst and the size of every fol-
licle with a mean diameter >10 mm, and total antral
follicle count (small follicles with a mean diameter
<10 mm) of each ovary will be obtained through
transvaginal ultrasound.
Pregnancy test
A urine pregnancy test will be performed to exclude
pregnancy.
Laboratory examination
1. Serum levels of sex hormone steroids, including
blood FSH, luteinising hormone (LH), estradiol
(E2), PRL, T, free testosterone, sex hormone-binding
globulin (SHBG) and TSH, will be evaluated on the
second day of the spontaneous period or a with-
drawal bleeding.
2. Fasting blood samples will be taken to determine
the metabolic and safety proﬁle, including fasting
blood glucose (FGLU), fasting insulin (FINS), C
peptide, HbA1c, triglycerides (TG), total cholesterol
(TC), apolipoprotein A 1 (ApoA1), apolipoprotein B
(ApoB), high-density lipoprotein cholesterol (HDL-C),
low-density lipoprotein cholesterol (LDL-C), and com-
plete blood count (CBC) as well as renal and LR
proﬁles.
3. The oral glucose tolerance test (OGTT) and insulin
release test with 75 g glucose will be performed in all
participants after an overnight fast. Blood samples
will be obtained to measure plasma glucose and
serum insulin at 0, 60 and 120 min during the OGTT
and insulin release test.
Complete questionnaires
Quality of life will be assessed using the health-related
quality-of-life questionnaire for PCOS (PCOSQ).31
Exclusion of other infertility factors of the couple
The semen quality of the husband and the tubal patency
of the patient, including hysterosalpingogram, hysterosal-
pingocontrast sonography (HyCoSy) or diagnostic lapar-
oscopy with chromotubation, will be assessed.
Preconception counselling
TORCH screening (Toxoplasmosis, Rubella,
Cytomegalovirus and Herpes virus), HIV screening and
folic acid prescription will be completed.
Progestin withdrawal
Progestin will be prescribed to induce withdrawal bleed-
ing with instructions to begin medication once eligibility
is determined.
Baseline visit
▸ Distribute the home pregnancy test strip and folate to
each participant.
▸ Distribute intercourse and menstrual journal logs to
each participant.
Take blood sample for repository and DNA analysis
A 20 mL blood sample will be collected from each par-
ticipant; 10 mL will be centrifuged for serum separation,
and the other 10 mL will be stored for DNA analysis.
Take faeces sample for microbiological detection
Treatment visit
The patients in the treatment group will be required to
use contraception during the ﬁrst 16 weeks, and all par-
ticipants will be instructed to have intercourse on a
regular basis during the letrozole treatment for ovula-
tion induction. The optimal frequency of intercourse
will be once every 2 or 3 days. A urine pregnancy test
will be performed after ovulation, and a serum proges-
terone level test will be performed in the local labora-
tory during the third week of the ovulation cycle. An
elevated level of progesterone >3 ng/mL is considered
to be a response.32 If the patient does not have ovula-
tion, the serum progesterone level test will be checked
every week until ovulation.
The transvaginal ultrasound examination will take
place in the anticipated luteal phase of the cycle, and it
will initially be scheduled for 2 weeks after the initiation
of medication with a window of 4 days on either side of
this day33 (ie, days 12–20, assuming a day 3 medication
start, or days 14–22, assuming a day 5 start). The ultra-
sound includes the endometrial thickness and echogeni-
city as well as the number, size and echogenic
characteristics of follicles/cysts in the ovary (including
an antral follicle count).
We will determine whether the patients have anovula-
tion response based on the serum progesterone level
and transvaginal ultrasound. There will be three possible
scenarios: ovulation, ovulation delay and non-ovulation.
(1) Ovulation: a serum progesterone level in the third
week >3 ng/mL and ultrasound showing presumptive
evidence of ovulation. A urine pregnancy test will be
performed to exclude pregnancy, the letrozole treat-
ment will be started on days 3–5 of menstruation, and
the dose of letrozole will be maintained. (2) Ovulation
delay: a serum progesterone level <3 ng/mL, but ultra-
sound showing that there is a evidence of follicular
development (ie, a follicle with a mean diameter
≥10 mm). In this case, we will wait for one more week,
and check the serum progesterone level again. A urine
pregnancy test will be performed to exclude pregnancy,
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letrozole treatment will be started on days 3–5 of menstru-
ation, and the dose of letrozole will be maintained.
(3) Non-ovulation: a serum progesterone level <3 ng/mL
and ultrasound showing no developing follicles with a
mean diameter ≥10 mm. These patients will receive letro-
zole on days 3–5 of their next cycle and will be instructed
to increase letrozole by one tablet per day for 5 days until
the maximum daily dose of 7.5 mg (3 pills) daily.
Every menstruation should be recorded, including the
date, volume and duration of menstruation.
End of pretreatment visit
1. Repeat the OGTT and insulin release test.
2. Collect menstrual journal logs.
Pregnancy visit (only with conception)
1. Complete the adverse event questionnaire.
2. Take blood samples for measuring serum quantitative
human chorionic gonadotropin (hCG) levels until
ultrasound shows the gestational sacs (the threshold
level of hCG is 2000–4000 IU/mL).33
3. Perform transvaginal ultrasound to determine the
number of gestational sacs and the location, dimen-
sions, presence and size of fetal structures and to
document the visualisation of fetal heart motion and
any pregnancy-related abnormalities.
End of treatment visit
1. Perform a physical examination, including vital signs,
height, weight, hip and waist measurements, and
repeat the hirsutism and acne assessments after the
end of treatment or pregnancy.
2. Repeat the measurements of serum levels of sex
hormone steroids and the metabolic proﬁle.
3. Repeat the OGTT and insulin release test.
4. Collect 20 mL of blood and store 10 mL after serum
separation with the other 10 mL for DNA analysis.
5. Repeat the PCOSQ.
6. Collect the menstrual and intercourse journal logs.
7. Record adverse events and concomitant medications.
8. Arrange follow-up for participants who have con-
ceived and obtain release of records for pregnancy
and neonatal records.
Follow-up visit
For those women who have an ongoing pregnancy,
arrangements will be made to follow the outcome of the
pregnancy at the end of the ﬁrst trimester and also after
delivery or termination of gestation. All pregnancies
(including multiples) will be followed to monitor weight,
glucose tolerance, blood pressure and fetal growth and to
determine the abortion rate, complication rate and preg-
nancy outcomes. The glucose tolerance will be measured
by OGTT in all pregnancies at 24–28 weeks of pregnancy.
Patients will be informed to notify the study personnel of
the outcome of the pregnancy, and we will obtain release
of record forms from treating physicians to obtain copies
of relevant medical records. Delivery records of both the
mother and newborn will be requested to determine the
birth weight, length of gestation, and any prenatal com-
plications of the mother or neonatal complications of the
infant. Phone contacts will be initiated if the patient has
not contacted the study personnel within 6 weeks of the
original estimated date of childbirth.
We will collect pregnancy outcome data, and we will
track the outcomes of all participants who have a positive
serum pregnancy screen during the course of this study.
We will record biochemical pregnancies (deﬁned as posi-
tive serum pregnancy screens without ultrasonically
detected pregnancies), ectopic pregnancies and all intra-
uterine pregnancy losses both before and after 20 weeks,
including missed abortions, spontaneous abortions, elect-
ive abortions, fetal deaths and stillbirths.
Outcome measures
Primary outcome
Live birth rate deﬁned as a delivery after ≥20 weeks
gestation.
Secondary outcomes
1. Ovulation rate;
2. Ongoing pregnancy rate (around 8–10 weeks
gestation);
3. Multiple pregnancy rate;
4. Miscarriage rate (loss of an intrauterine pregnancy
before 20 completed weeks of gestation);
5. Complications of pregnancy, including SGA, low
birth weight, preterm delivery, pre-eclampsia, ante-
partum haemorrhage, congenital anomaly and peri-
natal mortality;
6. Hormone proﬁle: FSH, LH, T, and SHBG;
7. Metabolic proﬁle: glucose and insulin concentrations,
C peptide, HbA1c, TC, TG, HDL-C, and LDL-C;
8. The homeostatic model assessment of insulin resist-
ance (HOMA-IR) index and the insulin response to
glucose assessed by calculating the area under the
curve during the OGTT and insulin release test per-
formance for glucose (AUCglu) and insulin
(AUCins) using the trapezoidal rule;34
9. Body composition: weight, BMI, waist-to-hip circum-
ference, FG score and acne lesion counts;
10. PCOSQ Questionnaire;
11. Side effect proﬁle.
Safety analysis
The major risks to the participant are side effects from
letrozole and acupuncture and the risks of pregnancy.
The most common adverse reactions (>20%) of letro-
zole are hot ﬂashes, arthralgia, ﬂushing, asthenia,
oedema, arthralgia, headache, dizziness, hypercholester-
olaemia, increased sweating, bone pain and musculoskel-
etal pain.35 The major risks of acupuncture are local
skin irritation, discomfort and vasovagal reactions during
the procedure.30 Adverse events will be categorised, and
the percentage of patients experiencing adverse events
and serious adverse events during the treatment period
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will be documented and reported to the Data and Safety
Monitoring Board (DSMB). χ2 Tests will be performed
to examine differences in the proportions of total events
and categories of adverse events.
Interim analysis
We propose not to perform an interim analysis, and the
ﬁnal data analysis will be completed after all live births
in the trial.
Statistics
Statistical tests
The Kolmogorov-Smirnov test will be used to test the
normal distribution of continuous variables. Continuous
variables will be shown as means±SDs if they are
normally distributed or as medians with IQRs if they
are not normally distributed. Statistical comparison
will be carried out according to the intention to treat
by Student’s t-test, Mann-Whitney U-test and Wilcoxon
signed ranks test for continuous variables and by χ2 tests
for dichotomous variables where appropriate. A p value
<0.05 will be considered statistically signiﬁcant.
Comparisons of variables such as live birth rate, ovula-
tion rate, ongoing pregnancy rate, multiple pregnancy
rate and miscarriage rate will include relative risk (RR)
and 95% CIs in addition to the χ2 test.
All statistical analyses of the data will be performed using
the SPSS program V.21.0 (SPSS, Chicago, Illinois, USA).
Sample size estimation
We hypothesise that the live birth rate after letrozole for
four cycles is 35% and the live birth rate after 16 weeks
of acupuncture pretreatment followed by letrozole for
four cycles is 55%. Thus, the difference between the two
groups will be 20% (δ=0.2); the α error and β error are
estimated as 0.05 and 0.20, respectively, and the power
will be 80%. This will require a sample size of 96 partici-
pants in both groups. A total of 60% of the women with
PCOS will be assumed to have IR (IR is deﬁned by
HOMA-IR, which is FINS concentration×fasting glucose
concentration/22.5, and a value ≥2.14 is considered to
be indicative of IR36), which will require 160 patients per
group. The sample size is inﬂated from 160 to 192 per
group to allow for a dropout rate of slightly over 20%,
and this gives a total of 384 cases for the two groups.
Imputation procedure for missing data
We will report reasons for withdrawal for both random-
isation groups and compare the reasons qualitatively.
The effect that any missing data might have on the results
will be assessed via sensitivity analysis of augmented data
sets. Dropouts (essentially participants who withdraw
consent for continued follow-up) will be included in the
analysis by modern imputation methods for missing data.
Data management and quality control of the data
Case report forms (CRFs) will be developed for recording
and depositing the individual patient data, and the web-
based public clinical platform ResMan will be used to
manage the data. Quality control of the data will be
handled at three different levels. The investigators are
required to ensure the accuracy of the data as the ﬁrst
level of control. The second level will include data moni-
toring and validation via ResMan on a regular basis by
the Data Coordination Centre (DCC). The third level will
be the site visits, during which data in ResMan will be
compared with the source documents. Identiﬁed errors
will be resolved between the DCC and the clinical sites.
Data monitoring and access
We will establish an independent DSMB. The responsibil-
ity of the DSMB will be to review and interpret the data
generated from the study, and its primary objectives will be
to ensure the safety of the study participants and the integ-
rity of the research data. The DSMB will hold regular con-
ference calls to review the protocol with respect to ethical
and safety standards, to monitor the safety of the trials, to
monitor the integrity of the data with respect to the ori-
ginal study design, and to provide advice on study
conduct. It will also review the progress of the trial, adjudi-
cate adverse events and decide on any premature closure
of the study.
The DCC will oversee the intrastudy data sharing
process with input from the DSMB. All PIs will be given
access to the cleaned data sets. Project data sets will be
housed on the ResMan database system for the study,
and all data sets will be password protected. The PIs will
have direct access to their own site’s data sets as well as
access to other sites’ data by request. To ensure conﬁ-
dentiality, data dispersed to project team members will
be blinded to any identifying participant information.
Auditing
An audit trail will be designed as another security
measure. This will ensure that only authorised additions,
deletions or alterations of information in the electronic
record will have occurred and will allow a means to
reconstruct signiﬁcant details about study conduct and
source data collection that are necessary to verify the
quality and integrity of the data. Computer-generated,
time-stamped audit trails will be implemented for track-
ing changes in the electronic source documentation.
Controls will be built to ensure that the date and time
of the system are correct. Dates and times will include
the year, month, day, hour and minute provided by inter-
national standard-setting agencies. The ability to change
the date or time will be limited to authorised personnel,
and such personnel will be notiﬁed if a system date or
time discrepancy is detected.
Internal safeguards will be built into the computerised
system. Data will be stored at the servers housed at
the First Afﬁliated Hospital of Guangzhou Medical
University with access overseen by professor TW.
Records will be regularly backed up, and record logs will
be maintained to prevent a catastrophic loss of data and
to ensure the quality and integrity of the data.
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Table 3 Composition and responsibilities for the research group
Composition Member name Affiliation Roles and responsibilities
PIs and research
physicians
Hongxia Ma
Ernest HY Ng
Elisabet Stener-Victorin
Juan Li
Maohua Lai
Hua Liu
Zhenxing Hu
Yongxia Zheng
Kewei Quan
Meifang Li
1st Affiliated Hospital, Guangzhou Medical University
The University of Hong Kong
Karolinska Institutet
1st Affiliated Hospital, Guangzhou Medical University
1st Affiliated Hospital, Guangzhou Medical University
1st Affiliated Hospital, Guangzhou Medical University
Xuzhou Maternity and Child Health Hospital
Hexian Memorial Affiliated Hospital of Southern
Medical University
1st Affiliated Hospital, Guangzhou Medical University
1st Affiliated Hospital, Guangzhou Medical University
Design and conduct of the study.
Preparation of protocol and revisions.
Preparation of the investigator’s SOP and CRFs.
Organising the SC meetings.
In each participating centre, a site investigator will be identified and
will be responsible for patient identification and recruitment, data
collection and completion of CRFs as well as follow-up of study
patients and adherence to the study protocol and SOP.
SC
Ernest HY Ng
Hongxia Ma
Elisabet Stener-Victorin
Juan Li
Taixiang Wu
Maohua Lai
Hua Liu
Zhenxing Hu
Yongxia Zheng
Kewei Quan
Meifang Li
Chair
The University of Hong Kong
PIs
1st Affiliated Hospital, Guangzhou Medical University
Karolinska Institutet
Co-investigators
1st Affiliated Hospital, Guangzhou Medical University
Chinese Clinical Trial Registry
Site investigators and research physicians
1st Affiliated Hospital, Guangzhou Medical University
1st Affiliated Hospital, Guangzhou Medical University
Xuzhou Maternity and Child Health Hospital
Hexian Memorial Affiliated Hospital of Southern
Medical University
1st Affiliated Hospital, Guangzhou Medical University
1st Affiliated Hospital, Guangzhou Medical University
Authorisation of the final study protocol.
All PIs will be SC members.
Reviewing the progress of the study and, if necessary, agreeing to
changes to the protocol and/or the SOP to facilitate the smooth
running of the study.
TMC (PIs,
research
physicians,
administrators)
Ernest HY Ng
Hongxia Ma
Elisabet Stener-Victorin
Taixiang Wu
Juan Li
Maohua Lai
Hua Liu
Zhenxing Hu
Yongxia Zheng
Kewei Quan
Meifang Li
The University of Hong Kong
1st Affiliated Hospital, Guangzhou Medical University
Karolinska Institutet
Chinese Clinical Trial Registry
1st Affiliated Hospital, Guangzhou Medical University
1st Affiliated Hospital, Guangzhou Medical University
1st Affiliated Hospital, Guangzhou Medical University
Xuzhou Maternity and Child Health Hospital
Hexian Memorial Affiliated Hospital of Southern
Medical University
1st Affiliated Hospital, Guangzhou Medical University
1st Affiliated Hospital, Guangzhou Medical University
Study planning.
Provide annual risk reports to the DSMB and the ethics committee.
Reporting serious unexpected suspected adverse events to the
DSMB.
Responsible for the trial master file.
Budget administration and contractual issues with individual
centres.
Advice for PIs.
Auditing of 6-month feedback forms and deciding when site visits
should occur.
Assistance with independent ethics committee applications.
Data verification.
Organisation of the central serum sample collection.
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Table 3 Continued
Composition Member name Affiliation Roles and responsibilities
DSMB Hongying Kuang
Mei Han
Min Hu
Heilongjiang University of Chinese Medicine
Beijing University of Chinese Medicine
Goteborg University
Review and interpret the data generated from the study.
Ensure the safety of the study participants.
Hold regular conference calls.
Review the protocol with respect to ethical and safety standards.
Monitor the safety of the trials.
Monitor the integrity of the data with respect to the original study
design.
Provide advice on study conduct.
Review the progress of the trial.
Adjudicate adverse events.
Decide on any premature closure of the study.
DCC Taixiang Wu Chinese Clinical Trial Registry Oversee the data collection and management (including quality
assurance/compliance measures).
Oversee the intrastudy data sharing process.
Generate and disclose the randomisation scheme for the study.
Design the password of the web-based ResMan database to
protect the safety of the data.
Publication
Committee
Ernest HY Ng
Hongxia Ma
Elisabet Stener-Victorin
Taixiang Wu
Juan Li
Maohua Lai
Zhenxing Hu
The University of Hong Kong
1st Affiliated Hospital, Guangzhou Medical University
Karolinska Institutet
Chinese Clinical Trial Registry
1st Affiliated Hospital, Guangzhou Medical University
1st Affiliated Hospital, Guangzhou Medical University
Xuzhou Maternity and Child Health Hospital
Publication of study reports.
Document the contributions to the study of each author.
Draft and revise the manuscript.
CRFs, case report forms; DCC, Data Coordination Centre; DSMB, Data and Safety Monitoring Board; PIs, principal investigators; ResMan, Research Management; SC, Steering Committee;
SOP, standard operating procedure; TMC, Trial Management Committee.
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ETHICS AND DISSEMINATION
All participants and their husbands will be asked to sign
a consent form prior to joining the study, and they will
be made fully aware that they are free to withdraw from
the study at any time. The results of this trial will be dis-
seminated in peer-reviewed journals and presented at
international meetings.
Confidentiality and privacy
The investigators have always maintained a strict privacy
policy. All correspondence to the department is held
conﬁdentially, and at no time will participants’ personal
and/or identifying information be shared outside of our
organisation for any reason.
All study participants have the right to access their per-
sonal data and known study results, if and when needed,
and they enjoy rights for the protection of the conﬁden-
tiality of their personal data such as those regarding the
collection, custody, retention, management, control and
use (including analysis or comparison) of the data.
By signing and dating this consent form, all participants
agree to and do give up, waive, disclaim, adjust or in any
way abrogate any of the aforementioned rights. For any
questions, they should consult our ofﬁce (020-83062452)
as to the proper monitoring or supervision of their per-
sonal data protection so that their full awareness and
understanding of the signiﬁcance of compliance with the
law governing the privacy of their data is assured.
For questions about the study or reporting of adverse
events, the participants should contact their physician.
Research group
The research group consists of the PIs and research phy-
sicians, the Steering Committee (SC), the Trial
Management Committee, the DSMB, the DCC and the
Publication Committee. The members will all have differ-
ent roles and responsibilities to guarantee that the research
is carried out scientiﬁcally and rigorously (table 3).
Protocol version and amendments
The ﬁrst version of the protocol was ﬁnished on 20 May
2014. After numerous discussions and amendments
by the authors and experts in the research group, there
are 10 versions of the protocol. Such amendments will
be agreed on by the SC and DSMB and will be approved
by the ethics committee prior to implementation.
Administrative changes to the protocol are minor correc-
tions and/or clariﬁcations that have no effect on the way
the study is to be conducted.
Dissemination policy
It is anticipated that there will be up to 10–20 authors
per major manuscript. The authorship order for the
participating sites will be based on participant recruit-
ment, data accuracy and promptness of data reporting
and will start at position 5 and go to position 15. Each
site’s PI will be responsible for documenting the contri-
butions to the study of that site’s authors.
The participants, all of whom belong to couples with
infertility, will beneﬁt from receiving treatment that
might offer an increased chance for pregnancy. This
study will help guide therapy for future couples with the
same issues, and establishing the evidence-based nature
of these practices is an important public health aim.
DISCUSSION
To the best of our knowledge, no studies have investi-
gated whether acupuncture pretreatment followed by
ovulation induction will increase the live birth rate
in women with PCOS. The present study is the ﬁrst
RCT to compare acupuncture pretreatment followed by
letrozole with letrozole alone on live birth in anovula-
tory infertile women with PCOS. The hypothesis is that
acupuncture pretreatment improves insulin sensitivity
and leads to a higher ovulation rate and live birth rate,
which is different from the available evidence suggest-
ing that acupuncture inﬂuences ovulation by affect-
ing the levels of various hormones. We are also
interested in the prospective effects of acupuncture on
women with PCOS, and complications of pregnancy
such as impaired glucose tolerance, gestational diabetes
mellitus, pregnancy-induced hypertension and pre-
eclampsia, SGA, low birth weight, preterm delivery,
pre-eclampsia, antepartum haemorrhage, congenital
anomaly, perinatal mortality and multiple pregnancies
will all be observed to verify the efﬁcacy of the treat-
ment in this study.
According to a recent systematic review,37 there are
no studies that have been designed to investigate live
birth—which is one of the important clinical outcomes
—and there is no evidence of a difference in preg-
nancy rate between true and sham acupuncture. Based
on this, live birth was chosen as the primary outcome
in this study, and we chose letrozole alone as the
control to replace placebo or sham acupuncture. In
addition, low numbers of participants is one of the
factors that has limited the quality of the studies per-
formed until now. A high-quality study with an adequate
sample size is urgently needed, and our estimates
suggest that 384 patients recruited from three hospitals
at the same time will ensure a sample size that is sufﬁ-
cient to test our hypothesis.
The study was designed in 2014, and the ﬁrst partici-
pant was randomised on 18 August 2015. At the time of
manuscript submission, we have recruited 90 patients
and the recruitment is ongoing.
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